Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy

<jats:sec> <jats:title/> <jats:p>To assess whether extended treatment with interferon improves the outcome of hepatitis B e antigen (HBeAg)–negative chronic hepatitis B, 101 consecutive patients were treated with 6 MU of interferon alfa 2b 3 times weekly for 24 months. During the 68–month study, 30 patients (30%) had a sustained response (<jats:italic toggle="yes">i.e.</jats:italic>, normal serum transaminase levels and undetectable hepatitis B virus DNA by non–polymerase chain reaction [PCR] assays), and 15 cleared serum surface antigen. Twenty–five nonresponders, 16 relapsers, and 30 who discontinued treatment were considered treatment failures. Multivariate analysis predicted a sustained response for young age (odds ratio, 0.94; 95% confidence interval, 0.89–0.99; <jats:italic toggle="yes">P</jats:italic> = .041) and high pretreatment serum levels of immunoglobulin M (IgM) anti–hepatitis B core antigen (HBc) (odds ratio, 4.52; 95% confidence interval, 1.63–12.5; <jats:italic toggle="yes">P</jats:italic> = .004). Liver disease progressed in none of the sustained responders but in 16 with treatment failure (0% vs. 22%, <jats:italic toggle="yes">P</jats:italic> = .002); hepatocellular carcinoma (HCC) developed with similar frequency in both groups (7%). Overall, estimated 8–year complication–free survival was longer for the 30 sustained responders than the 71 patients with treatment failure (90% vs. 60%, <jats:italic toggle="yes">P</jats:italic> < .001), but 8–year patient survival was similar in the 2 groups (100% and 90%). Short complication–free survival was predicted by failure to respond to interferon (hazard ratio, 7.8; 95% confidence interval, 1.8–34.0; <jats:italic toggle="yes">P</jats:italic> = .006) and high scores for liver fibrosis (hazard ratio, 1.71; 95% confidence interval, 1.17–2.50; <jats:italic toggle="yes">P</jats:italic> = .005). In conclusion, 24 months of treatment with interferon alfa 2b led to sustained disease suppression in a significant proportion of patients with HBeAg–negative chronic hepatitis B. (Hepatology 2003;37:756–763.)</jats:p> </jats:sec>